Surrogate Biochemical Markers: Precise Measurement for Strategic Drug and Biologics Development
- 1 May 1995
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 35 (5) , 464-470
- https://doi.org/10.1002/j.1552-4604.1995.tb04089.x
Abstract
More efficient drug and biologics development is necessary for future success of pharmaceutical and biotechnology companies. One way to achieve this objective is to use rationally selected surrogate markers to improve the early decision‐making process. Using typical clinical chemistry methods to measure biochemical markers may not ensure adequate precision and reproducibility. In contrast, using analytical methods that meet good laboratory practices along with rational selection and validation of biochemical markers can give those who use them a competitive advantage over those who do not by providing meaningful data for earlier decision making.Keywords
This publication has 14 references indexed in Scilit:
- How controversial are surrogate endpoints?Nature Biotechnology, 1994
- Coronary Angiographic Changes with Lovastatin Therapy: The Monitored Atherosclerosis Regression Study (MARS)Annals of Internal Medicine, 1993
- Angiotensin II Receptor Blockade: An Innovative Approach to Cardiovascular PharmacotherapyThe Journal of Clinical Pharmacology, 1993
- Pharmacodynamics, Clinical Indications, and Adverse Effects of HeparinThe Journal of Clinical Pharmacology, 1992
- Heparin Pharmacokinetics and PharmacodynamicsClinical Pharmacokinetics, 1992
- Surrogate Markers in AIDS: Where Are We? Where Are We Going?Annals of Internal Medicine, 1992
- Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic StudiesJournal of Pharmaceutical Sciences, 1992
- Cost of innovation in the pharmaceutical industryJournal of Health Economics, 1991
- Angiotensin converting enzyme inhibitors: Comparative structure, pharmacokinetics, and pharmacodynamicsCardiovascular Drugs and Therapy, 1990
- Simultaneous pharmacokinetic and pharmacodynamic modelingJournal of Pharmacokinetics and Biopharmaceutics, 1981